{"name":"National Research Center for Hematology, Russia","slug":"national-research-center-for-hematology-russia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"R-DA-EPOCH-21","genericName":"R-DA-EPOCH-21","slug":"r-da-epoch-21","indication":"Diffuse large B-cell lymphoma","status":"phase_3"},{"name":"R-DA-EPOCH-21 + auto-SCT","genericName":"R-DA-EPOCH-21 + auto-SCT","slug":"r-da-epoch-21-auto-sct","indication":"Diffuse large B-cell lymphoma","status":"phase_3"},{"name":"R-mNHL-BFM-90","genericName":"R-mNHL-BFM-90","slug":"r-mnhl-bfm-90","indication":"Non-Hodgkin lymphoma, particularly in children and young adults","status":"phase_3"},{"name":"R-mNHL-BFM-90 + auto-SCT","genericName":"R-mNHL-BFM-90 + auto-SCT","slug":"r-mnhl-bfm-90-auto-sct","indication":"Relapsed or refractory non-Hodgkin lymphoma (B-cell)","status":"phase_3"},{"name":"standard dose ARA-C","genericName":"standard dose ARA-C","slug":"standard-dose-ara-c","indication":"Acute myeloid leukemia (AML)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Mesenchymal stromal cells","genericName":"Mesenchymal stromal cells","slug":"mesenchymal-stromal-cells","indication":"Graft-versus-host disease (GVHD)","status":"marketed"}]}],"pipeline":[{"name":"Mesenchymal stromal cells","genericName":"Mesenchymal stromal cells","slug":"mesenchymal-stromal-cells","phase":"marketed","mechanism":"Mesenchymal stromal cells (MSCs) are bone marrow-derived multipotent cells that exert immunomodulatory and tissue-regenerative effects through paracrine signaling and direct cell-cell interactions.","indications":["Graft-versus-host disease (GVHD)","Acute myocardial infarction","Osteoarthritis","Systemic lupus erythematosus"],"catalyst":""},{"name":"R-DA-EPOCH-21","genericName":"R-DA-EPOCH-21","slug":"r-da-epoch-21","phase":"phase_3","mechanism":"R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab, doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone.","indications":["Diffuse large B-cell lymphoma"],"catalyst":""},{"name":"R-DA-EPOCH-21 + auto-SCT","genericName":"R-DA-EPOCH-21 + auto-SCT","slug":"r-da-epoch-21-auto-sct","phase":"phase_3","mechanism":"R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab with the EPOCH chemotherapy regimen, followed by an autologous stem cell transplant.","indications":["Diffuse large B-cell lymphoma"],"catalyst":""},{"name":"R-mNHL-BFM-90","genericName":"R-mNHL-BFM-90","slug":"r-mnhl-bfm-90","phase":"phase_3","mechanism":"R-mNHL-BFM-90 is a chemotherapy regimen used to treat certain types of non-Hodgkin lymphoma.","indications":["Non-Hodgkin lymphoma, particularly in children and young adults"],"catalyst":""},{"name":"R-mNHL-BFM-90 + auto-SCT","genericName":"R-mNHL-BFM-90 + auto-SCT","slug":"r-mnhl-bfm-90-auto-sct","phase":"phase_3","mechanism":"R-mNHL-BFM-90 is a rituximab-based chemotherapy regimen combined with autologous stem cell transplantation to treat non-Hodgkin lymphoma by targeting CD20+ B cells and providing high-dose chemotherapy with stem cell rescue.","indications":["Relapsed or refractory non-Hodgkin lymphoma (B-cell)"],"catalyst":""},{"name":"standard dose ARA-C","genericName":"standard dose ARA-C","slug":"standard-dose-ara-c","phase":"marketed","mechanism":"ARA-C (cytarabine) is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, leading to cell death.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)","Chronic myeloid leukemia (CML) in blast crisis","Lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxONF9YOFBvNEFHQTJwbHlKVWtyU3BiUUQ5bnRDUTE4d0lxNm5rcVJVbG1Bdmc4emoxY0phYnV2YUlhMWljbTRfRU1vMjFFcldFcGQ1X0VkRjI4MTRxRUNmWjhTTDFLS3lUUUMxWnlSZ25XbGVUTFF3bFVPWktZQTN5NElUcHN6d1ZPOV9sa2FMWklsbzZDZnNGcVF0X1c5U25JS1ZheUJidU52QmRvemlHRWNYOVg3N0tNVWc2LU93cFo?oc=5","date":"2026-02-19","type":"pipeline","source":"The Pharma Letter","summary":"Russia tightens requirements for foreign drug to be included in list of vitals - The Pharma Letter","headline":"Russia tightens requirements for foreign drug to be included in list of vitals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPM1ZiZFdZR0w4RGhPNFVQYURJWDk5RFh0Mi0ySTFCd1dvcFREMGJjOWM2bGt5WHNaUVNCQTlfMzRrRmV2QmxjV0c0ckIxcVpKVDJiVTVYdlpsM2dVU05nMG9uenNqSWhPS2w1c0R1OGtKY3E0UjZaRHdpbFBiOFhDRThPUkJxVUVqMjNKRkU4bThWSkVnMlRGM9IBmAFBVV95cUxPM1ZiZFdZR0w4RGhPNFVQYURJWDk5RFh0Mi0ySTFCd1dvcFREMGJjOWM2bGt5WHNaUVNCQTlfMzRrRmV2QmxjV0c0ckIxcVpKVDJiVTVYdlpsM2dVU05nMG9uenNqSWhPS2w1c0R1OGtKY3E0UjZaRHdpbFBiOFhDRThPUkJxVUVqMjNKRkU4bThWSkVnMlRGMw?oc=5","date":"2025-12-24","type":"pipeline","source":"Новости GxP","summary":"R-Pharm expands its portfolio of proprietary anti-tumor drugs - Новости GxP","headline":"R-Pharm expands its portfolio of proprietary anti-tumor drugs - Новости GxP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTE1TeDhjQ18xWEZvZmZRUUozVi1jNnFFalA3ZUtjZUxQZEV6RTVaQWkwVGxTZFlWV3oxRVpkeU9JS0xYTEFITGpLczNMNA?oc=5","date":"2025-02-15","type":"pipeline","source":"Oncodaily","summary":"OncoThon 2025 - Oncodaily","headline":"OncoThon 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBoTE9Rb29jRnA5TW1KOHdzQXBOQUt4c3VXcC1XOE14Uk5HRmNUWTBaZlVFMERIQ3ZnejJWRDhUbE5aR3FUMTRKTGpTbFNwZzhxckRmaERuWlBUT0lVdXlv?oc=5","date":"2024-09-05","type":"trial","source":"nature.com","summary":"Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3 -mutated acute myeloid leukemia - nature.com","headline":"Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3 ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYjA2NGhCT3Fad0pKTGJyUk5CVVQyQzExTUdERDZHNFV0YzBENTctTS1RZExGZFA3bmNKNnBtdjVLem5OS1pQV1luLWlFd2hIUXA0bGZ1Y0JhM1pYWnR0YVYxOEZudjI5MXAtSnBWRzFseHVieUFVbmR5R3RBZXI2N25CMGtCTHhkcWh0RHFrNFdlc2pUbnZOTjI2TTFNR3IybHdtbElTc0hlUQ?oc=5","date":"2023-10-17","type":"pipeline","source":"Cancer Nursing Today","summary":"JAK2 and MPL mRNA Expression Linked With Aspirin Resistance in MPL - Cancer Nursing Today","headline":"JAK2 and MPL mRNA Expression Linked With Aspirin Resistance in MPL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBFQmZfLUdFcFJQNjdPMkEwSUZKM2p4Vm1MZ2VJU25PdGVtZi1LT3huSFNyVGtkWkRyU3BEbjB5VTNQSDBTMlE1aTNNVzh6RkhYdy0wSGZmUTdOUU9FOGNv?oc=5","date":"2023-01-30","type":"trial","source":"nature.com","summary":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL - nature.com","headline":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB5YzRoNFIwZVFIVk1mUERMeXN6RjRfRmpBb2xIYjlXSTZnTGZub3c0Wjd1elkxb3E0UE1SQ09TNzdBOV9HTTdVRVlJcnhuQXg4Q2w5b2p4cC00ZTlZNzVZ?oc=5","date":"2022-04-05","type":"trial","source":"nature.com","summary":"Studying severe long COVID to understand post-infectious disorders beyond COVID-19 - nature.com","headline":"Studying severe long COVID to understand post-infectious disorders beyond COVID-19","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE8xY2JJUVViNWVWOTdyd3BSdllQZ1RheGZaVlNFS2RrS19SREpWSVVjNUgtaHQ5czVMQUNYc2xIYVNHYVI1WWJOdDVfdTVGUU1Zd0VGOVZMbnNpZXNjWEtZ?oc=5","date":"2021-11-01","type":"trial","source":"nature.com","summary":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study - nature.com","headline":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE4wMC1MeDZNVzRITDhWMTBPLTNZc0Z3UWNGbHFnV1NVVF8wYl9IWW9tbDdGdnlPM1E1OHRoWnpIZTRuRC1Qa2c5ZnBSRi1QWkZ2alNyYmJ4QVZtQ09kTVNabWpzX3BhZk1maURqMDBsV3I?oc=5","date":"2021-10-03","type":"pipeline","source":"Wiley Online Library","summary":"Antigen-Specific Stimulation and Expansion of CAR-T Cells Using Membrane Vesicles as Target Cell Surrogates - Wiley Online Library","headline":"Antigen-Specific Stimulation and Expansion of CAR-T Cells Using Membrane Vesicles as Target Cell Surrogates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOcUpsVUVqckQ1SDRXN0pneGJGNklIemNabjFwSnp6Zko2aEQ0cG1STW1ZUkpMS3VFak5kbDdwczVzOUVaZ0NhaHkwSUpjX0FONWpvbHFFa212dFlNUjNyVGo4QjNkZzZSMXVRcDZic1QtT29xWVVsaEJVRkJFRkxfSFFvTTB0ckE?oc=5","date":"2021-03-08","type":"pipeline","source":"medicaldevice-network.com","summary":"Illumina and R-Pharm receive device registration for sequencing platforms - medicaldevice-network.com","headline":"Illumina and R-Pharm receive device registration for sequencing platforms - medicaldevice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWW9mcjRWVDFmb2tMU0NVcXpEclpRWlNkdFBXcy13OWZ4cFBHOE5iQXFWbVp2Qno2MDRXS0dERzlJeEN3NkY4eHlEMmlrUnYtZ1dEVHB1REtnN3hyVXNVOWEwN1YwcWY5X2FDaEFTUF9BN0xlN19XeWdUY1JPSU1iTEJuOFdtc2lvd045QjJHM2JqR3M0bWVtM2gwOXRnNklZY0JTbTNSRTc5MG5wRGNYNmR1R09mZWlIYVJZaHpnTG9ITGJoN3FWV2wxamZIaDB3TkJoN3QwM3FWU3REc3hIVjF1Yw?oc=5","date":"2020-02-12","type":"pipeline","source":"The Moscow Times","summary":"‘People Could Lose Their Lives’: Medicine Shortages in Russia Have Left Patients Fending for Themselves - The Moscow Times","headline":"‘People Could Lose Their Lives’: Medicine Shortages in Russia Have Left Patients Fending for Themselves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1nNllMMkN0Y2F0UklfejBOclVpVEFIdmtGa2FXRXdXSjNyeV9NeEhSNTl5dnlENzdLR09PRnZpNllIREJ0UmN5Z2x5LVJGWllBbHg4cFZxMndYRml3TkRF?oc=5","date":"2020-02-05","type":"pipeline","source":"nature.com","summary":"Genomic footprints of activated telomere maintenance mechanisms in cancer - nature.com","headline":"Genomic footprints of activated telomere maintenance mechanisms in cancer","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":2,"phase_3":4},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}